Christina Smolke | |
---|---|
![]() | |
Nationality | American |
Scientific career | |
Fields | Synthetic biology |
Institutions | Stanford University |
External videos | |
---|---|
![]() |
Christina Smolke is an American synthetic biologist whose primary research is in the use of yeast to produce opioids for medical use. [1] [2] She is a Full Professor of Bioengineering and of Chemical Engineering at Stanford University. [3] She is the editor of The metabolic pathway engineering handbook (2010). [4] She is an advisory board member for Integrative Biology . [5] She is also the CEO and Cofounder of Antheia Bio, a bioengineering company.
Smolke and her laboratory team at Stanford University have pioneered work into the creation of a synthetic enzyme that converts reticuline, a key element of opioids. [6] [7] The process adds five genes from two different organisms to the yeast cells. Three of these genes come from the poppy, and the others from a bacterium that lives on poppy plant stalks. They produced the first narcotic using synthetic biology. [8] [9]
Smolke has also done work on cancer cells with Maung Nyan Win, designing molecules from RNA that can identify biomarkers in the cellular state of diseased cells. Such molecules could act as computational devices within the cell, detecting states and determining whether or not to carry out a particular action. They have the potential to be used in "smart" drug delivery systems, to ensure that healthy cells will not be affected by treatments. Potential applications are being investigated at the City of Hope Cancer Center. [10] [11] [12]
{{cite web}}
: |author=
has generic name (help)